ValuEngine upgraded shares of Retrophin (NASDAQ:RTRX) from a buy rating to a strong-buy rating in a research note published on Wednesday.

Several other equities analysts also recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Retrophin in a report on Tuesday, October 30th. They issued a buy rating and a $44.00 price target on the stock. Zacks Investment Research upgraded shares of Retrophin from a sell rating to a hold rating in a report on Thursday, September 27th. BidaskClub upgraded shares of Retrophin from a hold rating to a buy rating in a report on Tuesday, August 28th. Finally, Canaccord Genuity assumed coverage on shares of Retrophin in a report on Friday, August 17th. They issued a buy rating on the stock. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $43.50.

Shares of Retrophin stock traded down $1.28 during midday trading on Wednesday, hitting $25.77. The company had a trading volume of 208,582 shares, compared to its average volume of 301,596. Retrophin has a 12-month low of $20.09 and a 12-month high of $33.00. The company has a quick ratio of 4.99, a current ratio of 5.04 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.12 billion, a P/E ratio of -17.18 and a beta of 1.19.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.39). Retrophin had a negative return on equity of 35.43% and a negative net margin of 69.38%. The business had revenue of $40.70 million during the quarter, compared to analyst estimates of $44.36 million. During the same quarter last year, the company posted $0.15 EPS. Retrophin’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, research analysts anticipate that Retrophin will post -2.67 earnings per share for the current fiscal year.

In related news, CEO Steve Aselage sold 12,000 shares of the stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $32.00, for a total value of $384,000.00. Following the transaction, the chief executive officer now owns 257,883 shares in the company, valued at approximately $8,252,256. The sale was disclosed in a filing with the SEC, which is available through this link. 3.67% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Trexquant Investment LP acquired a new stake in shares of Retrophin during the 2nd quarter worth approximately $273,000. Hartford Investment Management Co. acquired a new stake in shares of Retrophin during the 2nd quarter worth approximately $216,000. Sei Investments Co. acquired a new stake in shares of Retrophin during the 2nd quarter worth approximately $141,000. Algert Global LLC acquired a new stake in shares of Retrophin during the 2nd quarter worth approximately $358,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of Retrophin by 1,404.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 272,328 shares of the biopharmaceutical company’s stock worth $7,424,000 after purchasing an additional 254,232 shares during the period.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: What is Cost of Capital?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.